These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1242 related articles for article (PubMed ID: 28011478)

  • 21. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
    Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
    Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
    Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
    J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M; Fei Z; Zhang G
    Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
    Liu Y; Sun L; Su X; Guo S
    Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sorafenib-mediated targeting of the AAA⁺ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death.
    Yi P; Higa A; Taouji S; Bexiga MG; Marza E; Arma D; Castain C; Le Bail B; Simpson JC; Rosenbaum J; Balabaud C; Bioulac-Sage P; Blanc JF; Chevet E
    Mol Cancer Ther; 2012 Dec; 11(12):2610-20. PubMed ID: 23041544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma.
    Wei X; Tang C; Lu X; Liu R; Zhou M; He D; Zheng D; Sun C; Wu Z
    Oncotarget; 2015 Jul; 6(21):18389-405. PubMed ID: 26158762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
    Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
    Zhai B; Hu F; Yan H; Zhao D; Jin X; Fang T; Pan S; Sun X; Xu L
    PLoS One; 2015; 10(9):e0138485. PubMed ID: 26381511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
    Lo Re O; Panebianco C; Porto S; Cervi C; Rappa F; Di Biase S; Caraglia M; Pazienza V; Vinciguerra M
    J Cell Physiol; 2018 Feb; 233(2):1202-1212. PubMed ID: 28471474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF
    Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
    Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL
    Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A small interfering RNA targeting vascular endothelial growth factor efficiently inhibits growth of VX2 cells and VX2 tumor model of hepatocellular carcinoma in rabbit by transarterial embolization-mediated siRNA delivery.
    Zou Y; Guo CG; Yang ZG; Sun JH; Zhang MM; Fu CY
    Drug Des Devel Ther; 2016; 10():1243-55. PubMed ID: 27069355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
    Wei G; Wang M; Hyslop T; Wang Z; Carr BI
    Int J Cancer; 2010 Dec; 127(12):2949-58. PubMed ID: 21351273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
    Honma Y; Shimizu S; Takehara T; Harada M
    J Gastroenterol; 2014 Mar; 49(3):517-26. PubMed ID: 23543326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib.
    Mao K; Zhang J; He C; Xu K; Liu J; Sun J; Wu G; Tan C; Zeng Y; Wang J; Xiao Z
    Cancer Lett; 2014 Oct; 352(2):245-52. PubMed ID: 25034398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
    Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
    Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
    Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
    BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
    Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 63.